Skip to main content
. 2022 Jun 8;36(8):2050–2063. doi: 10.1038/s41375-022-01617-x

Fig. 6. Investigation of metabolic alterations upon CD147-KD in vivo.

Fig. 6

A Non-targeted profiling of metabolites in a mouse xenotransplant model that differ between CD147-KiJK-1 tumors and controls with an absolute log2 fold change >0.5 (mean ± SEM, n = 2 for controls, n = 3 for CD147-KD). B Concentrations of glycolytic metabolites and TCA cycle intermediates in CD147-KiJK tumors and controls (mean ± SEM, n = 2 for controls, n = 3 for CD147-KD). C Changed metabolite ratio α-ketoglutarate (AKG) to citrate in CD147- KiJK tumors and controls (mean ± SEM, n = 2 for controls, n = 3 for CD147-KD) and in SUDHL-1 and KiJK CD147-KD cells compared to controls (n = 1 biological replicate per cell line) indicates shift of metabolism to reductive glutaminolysis due to compromised mitochondrial quality. Unpaired t-test, *p < 0.05.